Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Novartis Pharmaceuticals Corporation et al v. Amneal Pharmaceuticals LLC et al
Case Number:
1:15-cv-01025
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 27, 2016
Novartis, Amneal Settle Exelon Patch Infringement Fight
Novartis Pharmaceuticals Corp. and Amneal Pharmaceuticals Inc. have settled a suit accusing generic drugmaker Amneal of infringing two patents when applying to sell its own version of the dementia-treatment patch, Exelon, according to an order signed Wednesday in Delaware federal court.
-
November 06, 2015
Novartis Sues Amneal, Dr. Reddy's Over Dementia Patches
Novartis Pharmaceuticals Corp. and the co-owner of some of its patents filed a pair of suits in Delaware federal court Thursday over generic-drug makers Dr. Reddy's Laboratories Ltd. and Amneal Pharmaceuticals Inc.'s plans to make and market generic versions of Novartis' Exelon patch used to treat dementia associated with Parkinson's or Alzheimer's disease.